AVITA Medical, Inc. (RCEL)

11.20 +0.26 (+2.38%) USD  |  NASDAQ  |  Sep 04, 16:00
11.16 -0.04 (-0.36%) After-Hours: 20:00
More

AVITA Medical SG&A Expense (TTM) : 81.89M for June 30, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for RCEL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 81.89M
March 31, 2026 83.32M
December 31, 2025 85.65M
September 30, 2025 82.72M
June 30, 2025 88.17M
March 31, 2025 91.01M
December 31, 2024 91.39M
September 30, 2024 88.12M
June 30, 2024 80.05M
March 31, 2024 72.39M
December 31, 2023 65.62M
September 30, 2023 59.32M
June 30, 2023 53.08M
March 31, 2023 47.72M
December 31, 2022 45.24M
September 30, 2022 43.00M
June 30, 2022 41.66M
March 31, 2022 37.86M
June 30, 2021 33.96M
March 31, 2021 34.86M
December 31, 2020 25.78M
September 30, 2020 18.78M
June 30, 2020 10.31M
March 31, 2020 0.00
December 31, 2019 0.00
Date Value
September 30, 2019 0.00
June 30, 2019 0.00
March 31, 2019 0.00
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 0.00
March 31, 2018 0.00
December 31, 2017 0.00
September 30, 2017 0.00
June 30, 2017 0.00
March 31, 2017 0.00
December 31, 2016 0.00
September 30, 2016 0.00
June 30, 2016 0.00
March 31, 2016 0.00
December 31, 2015 0.00
September 30, 2015 0.00
June 30, 2015 0.00
March 31, 2015 0.00
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 0.00
March 31, 2014 0.00
December 31, 2013 0.00
September 30, 2013 0.00

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Halozyme Therapeutics, Inc. 238.00M
Iovance Biotherapeutics, Inc. 149.18M
Amgen, Inc. 7.019B
Editas Medicine, Inc. 45.51M
Arcus Biosciences, Inc. 106.00M